Cala^®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ^® Plus system, the next-generation of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson’s disease (PD). Cala kIQ Plus is the latest advancement in TAPS^® technology – introducing new therapy modes and adaptive calibration designed to optimize tremor relief and personalize treatment providing patients with an intuitive experience whenever tremor control is needed.

“Cala continues to elevate the patient experience and therapy outcomes by advancing wearable neuromodulation technology that treats action hand tremor in essential tremor and Parkinson’s disease. The Cala kIQ Plus system gives patients more control over how, when and where TAPS Therapy is delivered for tremor management,” said Cala CEO Deanna Harshbarger. “We will present the latest data on Cala kIQ Plus at the American Academy of Neurology conference in Chicago.”

Cala will showcase Cala kIQ Plus at AAN 2026 (Booth Number 5024). Clinical study data on Cala kIQ Plus showing improved efficacy with therapy modes will be presented on Monday, April 20 at 11:45 am CT in poster presentation P5-005 entitled, “Optimizing Transcutaneous Afferent Patterned Stimulation Therapy: Comparison of Variable Waveforms Reveals Increased Responder Rates and Bilateral Tremor Improvement in Essential Tremor.”